Abstract:P>Background and objective: CYP2C9 is the major contributor to gliclazide metabolic clearance in vitro, while the pharmacokinetics of gliclazide modified release are affected mainly by CYP2C19 genetic polymorphisms in vivo. This study aims to investigate the influence of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers. Methods: Eighteen healthy Han subjects with various combinations of CYP2C9 and CYP2C19 genotypes received 80 mg gliclazide. Plasma gliclazide concentrations were measured by a liquid chromatography-tandem mass spectrometry method for 84 h and plasma glucose and insulin levels were measured up to 15 h post-dose. Results and discussion: There was no difference in either pharmacokinetic and or pharmacodynamic parameters of gliclazide when group A (CYP2C9*1/*1, CYP2C19 extensive metabolizers) was compared with group B (CYP2C9*1/*3, CYP2C19 *1/*1). When group C (CYP2C9*1/*1 and CYP2C19 poor metabolizers) was compared with group A, the AUC(0-infinity) and C(max) in group C were significantly higher [83 center dot 94 +/- 40 center dot 41 vs. 16 center dot 39 +/- 5 center dot 10 mu g center dot h/mL (P = 0 center dot 000) and 1 center dot 50 +/- 0 center dot 85 vs. 0 center dot 45 +/- 0 center dot 18 mu g/mL (P = 0 center dot 000)], and the oral clearance was significantly lower [1 center dot 17 +/- 0 center dot 63 vs. 5 center dot 38 +/- 1 center dot 86 L/h (P = 0 center dot 000)]. The half-life of gliclazide was also significantly prolonged in group C subjects when compared with that of group A (33 center dot 47 +/- 12 center dot 39 vs. 19 center dot 34 +/- 10 center dot 45 h), but the difference was not significant (P = 0 center dot 052). The increase in serum glucose level at 11 h after dosing (Delta C(glu11)) in group C was significantly higher than that of group A (-1 center dot 08 +/- 0 center dot 42 vs. 0 center dot 22 +/- 1 center dot 01 mmol/L, P = 0 center dot 022). The corresponding insulin levels showed no difference between the two groups. Conclusion: CYP2C9*3 was not associated with any change in the disposition of gliclazide. CYP2C19 polymorphisms appear to exert the dominant influence on the pharmacokinetics of gliclazide in healthy Chinese Han subjects, and may also affect the observed pharmacodynamics of the drug as a result.

[Impact of Cytochrome P450 CYP2C9 Variant Allele CYP2C9 * 3 on the Pharmacokinetics of Glibenclamide and Lornoxicam in Chinese Subjects].

Effect of the CYP2C9*3 allele on lornoxicam metabolism.

Identification and Functional Assessment of EightCYP3A4Allelic Variants39–46Detected in the Chinese Han Population

Lornoxicam Pharmacokinetics in Relation to Cytochrome P450 2C9 Genotype.

Role Of Cyp2c9 And Its Variants (Cyp2c93 And Cyp2c913) In The Metabolism Of Lornoxicam In Humans

OATP1B3 (699G>A) and CYP2C92, 3 significantly influenced the transport and metabolism of glibenclamide and glipizide

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects.

Influence of CYP2C9 Polymorphism on the Pharmacokinetics of Gliquidone in Chinese Healthy Subjects

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers: Influenceof CYP2C9 and CYP2C19 genetic polymorphisms

Effect of CYP2C9 and SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of nateglinide in healthy Chinese male volunteers

CYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patients.

Effects of CYP2C8 and SLCO1B1 Genetic Polymorphisms on Repaglinide Pharmacokinetics: A Systematic Review and Meta-Analysis

Identification Of A Novel Variant Cyp2c9 Allele In Chinese

In Vitro and in Vivo Characterization of 13 CYP2C9 Allelic Variants Found in Chinese Han Population

CYP2C9 and OATP1B1 Genetic Polymorphisms Affect the Metabolism and Transport of Glimepiride and Gliclazide.

Influence of Cyp2c19 Loss-Of-Function Variants on the Metabolism of Clopidogrel in Patients from North-Western China

Effects of Functional CYP2C8,CYP2C9,CYP3A5,and ABCB1 Genetic Variants on the Pharmacokinetics of Insulin Sensitizer Pioglitazone in Chinese Han Individuals

CYP3A53 and CYP3A418 Single Nucleotide Polymorphisms in a Chinese Population.

Influence of Cyp2c9 and Cyp2c19 Genetic Polymorphisms on Pharmacokinetics and Pharmacodynamics of Gliclazide in Healthy Chinese Han Volunteers

The G-113a Polymorphism In Cyp1a2 Affects The Caffeine Metabolic Ratio In A Chinese Population

In vitro assessment of 36 CYP2C9 allelic isoforms found in the Chinese population on the metabolism of glimepiride.